IGSF8 is an innate immune checkpoint and cancer immunotherapy target
IGSF8, aberrantly expressed on malignant cells, functions as an innate immune checkpoint that inhibits cytotoxicity of natural killer cells. A monoclonal antibody targeting IGSF8 alone, or in combination with immune checkpoint blockade, shows therapeutic potential in preclinical models.